Figure 7. FXI and FXa inhibitors abrogated distal platelet CD62P expression and microaggregate formation under shear.

Whole blood, treated with 14E11, 1A6, rivaroxaban or melagatran at indicated concentrations, was perfused over a collagen-coated chambers immediately after recalcification; PBS or DMSO was used as vehicle. In parallel, whole blood samples were collected after treatment with vehicle or inhibitor, and incubated with TRAP-6 (10 μg/ml) or vehicle for 5 min. Data are reported as (A) mean ± SEM percentage of CD62P-positive platelets, or (B) mean ± SEM platelet microaggregate count versus 10⁴ gated single platelets in gated population of at least three experiments. The maximal CD62P expression levels or microaggregate counts after 5 mins of perfusion are shown in the graphs for each treatment.